Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 182

1.

Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge.

Baird JR, Byrne KT, Lizotte PH, Toraya-Brown S, Scarlett UK, Alexander MP, Sheen MR, Fox BA, Bzik DJ, Bosenberg M, Mullins DW, Turk MJ, Fiering S.

J Immunol. 2013 Jan 1;190(1):469-78. doi: 10.4049/jimmunol.1201209. Epub 2012 Dec 7.

2.

Avirulent Toxoplasma gondii generates therapeutic antitumor immunity by reversing immunosuppression in the ovarian cancer microenvironment.

Baird JR, Fox BA, Sanders KL, Lizotte PH, Cubillos-Ruiz JR, Scarlett UK, Rutkowski MR, Conejo-Garcia JR, Fiering S, Bzik DJ.

Cancer Res. 2013 Jul 1;73(13):3842-51. doi: 10.1158/0008-5472.CAN-12-1974. Epub 2013 May 23.

3.

Intracranial paracrine interleukin-2 therapy stimulates prolonged antitumor immunity that extends outside the central nervous system.

Ewend MG, Thompson RC, Anderson R, Sills AK, Staveley-O'Carroll K, Tyler BM, Hanes J, Brat D, Thomas M, Jaffee EM, Pardoll DM, Brem H.

J Immunother. 2000 Jul-Aug;23(4):438-48.

PMID:
10916753
4.

Potent activity of soluble B7-IgG fusion proteins in therapy of established tumors and as vaccine adjuvant.

Sturmhoefel K, Lee K, Gray GS, Thomas J, Zollner R, O'Toole M, Swiniarski H, Dorner A, Wolf SF.

Cancer Res. 1999 Oct 1;59(19):4964-72.

5.

IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma.

Ma HL, Whitters MJ, Konz RF, Senices M, Young DA, Grusby MJ, Collins M, Dunussi-Joannopoulos K.

J Immunol. 2003 Jul 15;171(2):608-15.

6.

Regulation gene expression of miR200c and ZEB1 positively enhances effect of tumor vaccine B16F10/GPI-IL-21 on inhibition of melanoma growth and metastasis.

Wang X, He X, Zhao F, Wang J, Zhang H, Shi F, Zhang Y, Cai K, Dou J.

J Transl Med. 2014 Mar 14;12:68. doi: 10.1186/1479-5876-12-68.

7.

Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma.

Oniki S, Nagai H, Horikawa T, Furukawa J, Belladonna ML, Yoshimoto T, Hara I, Nishigori C.

Cancer Res. 2006 Jun 15;66(12):6395-404.

8.

Cyclooxygenase 2 inhibition promotes IFN-gamma-dependent enhancement of antitumor responses.

Sharma S, Zhu L, Yang SC, Zhang L, Lin J, Hillinger S, Gardner B, Reckamp K, Strieter RM, Huang M, Batra RK, Dubinett SM.

J Immunol. 2005 Jul 15;175(2):813-9.

9.

Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor T cell immunity.

Lonsdorf AS, Kuekrek H, Stern BV, Boehm BO, Lehmann PV, Tary-Lehmann M.

J Immunol. 2003 Oct 15;171(8):3941-6.

11.
12.

Antiangiogenic and antitumor activities of IL-27.

Shimizu M, Shimamura M, Owaki T, Asakawa M, Fujita K, Kudo M, Iwakura Y, Takeda Y, Luster AD, Mizuguchi J, Yoshimoto T.

J Immunol. 2006 Jun 15;176(12):7317-24.

13.

Transient Foxp3(+) regulatory T-cell depletion enhances therapeutic anticancer vaccination targeting the immune-stimulatory properties of NKT cells.

Mattarollo SR, Steegh K, Li M, Duret H, Foong Ngiow S, Smyth MJ.

Immunol Cell Biol. 2013 Jan;91(1):105-14. doi: 10.1038/icb.2012.58. Epub 2012 Oct 23.

PMID:
23090488
14.
15.

Attenuated Toxoplasma gondii Stimulates Immunity to Pancreatic Cancer by Manipulation of Myeloid Cell Populations.

Sanders KL, Fox BA, Bzik DJ.

Cancer Immunol Res. 2015 Aug;3(8):891-901. doi: 10.1158/2326-6066.CIR-14-0235. Epub 2015 Mar 24.

16.

Macrophage colony-stimulating factor complementary DNA: a candidate for gene therapy in metastatic melanoma.

Walsh P, Dorner A, Duke RC, Su LJ, Glode LM.

J Natl Cancer Inst. 1995 Jun 7;87(11):809-16.

PMID:
7791230
17.

Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines.

Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT, Storkus WJ.

J Exp Med. 1996 Jan 1;183(1):87-97.

18.

Induction of potent antitumor immunity by in situ targeting of intratumoral DCs.

Furumoto K, Soares L, Engleman EG, Merad M.

J Clin Invest. 2004 Mar;113(5):774-83.

19.

Targeting tumors with nonreplicating Toxoplasma gondii uracil auxotroph vaccines.

Fox BA, Sanders KL, Chen S, Bzik DJ.

Trends Parasitol. 2013 Sep;29(9):431-7. doi: 10.1016/j.pt.2013.07.001. Epub 2013 Aug 5. Review.

20.

Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.

Choi KJ, Kim JH, Lee YS, Kim J, Suh BS, Kim H, Cho S, Sohn JH, Kim GE, Yun CO.

Gene Ther. 2006 Jul;13(13):1010-20. Epub 2006 Mar 9.

PMID:
16525479

Supplemental Content

Support Center